急性期川崎病患儿血浆TSP-1、PAF水平变化及临床意义

Abstract
Figure/Table
References (23)
Related Citation (7)

Download: PDF (555 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the changes and clinical significance of plasma platelet activating factor (PAF) and thrombospondin-1 (TSP-1) levels in children with acute Kawasaki disease (KD). Methods A total of 107 children with KD who were treated in West China Hospital of Sichuan University ("our hospital" for short) from January 2015 to January 2018 were selected as KD group. They were divided into coronary artery expansion group (n = 43) and non-coronary expansion group (n = 64) according to echocardiographic findings. Thirty cases of indirect inguinal hernia in our hospital in the same period were selected as control group. The levels of TSP-1, PAF and platelets（PLT） in the acute, subacute and recovery phases of the KD group and the control group were detected by enzyme-linked immunosorbent assay (ELISA). The differences among different indicators of each group were compared. Results The levels of plasma PAF, TSP-1 and PLT in KD group with the acute phase were significantly higher than those in control group (all P < 0.05). The plasma levels of PAF and TSP-1 in KD group increased in recovery, subacute and acute stages (all P < 0.05). The plasma PAF level in coronary artery injury group was significantly higher than that in non-coronary injury group (P < 0.05), but there was no significant difference in plasma PAF level between KD group in the subacute and recovery phases and non-coronary injury group (P > 0.05). There was no significant differences in TSP-1 level and PLT count between coronary artery injury group in the acute, subacute, and recovery phase and non-coronary injury group (P > 0.05). There was no correlation between plasma TSP-1 and PAF, PLT in KD group in the acute phase（r = 0.314, 0.051, P > 0.05）, but there was a significant positive correlation between PAF and PLT (r = 0.614, P < 0.05). Conclusion The plasma levels of PAF and TSP-1 are significantly increased in the acute phase of KD, and PAF is significantly increased in coronary artery injury. Both PAF and TSP-1 are involved in the occurrence and development of KD, and might be used as markers for early diagnosis of KD.

Key words： Kawasaki disease Acute phase Platelet activating factor Thrombospondin-1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIANG Yongmei1
	2 CHEN Tingting3 ZHOU Kaiyu4 LAI Meimei5

Cite this article:

JIANG Yongmei1,2 CHEN Tingting3 ZHOU Kaiyu4 LAI Meimei5. Changes of plasma TSP-1 and PAF level in children with acute Kawasaki disease and their clinical significance[J]. 中国医药导报, 2019, 16(19): 113-116.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I19/113

[1] 杨波，朱义杰，罗军，等.川崎病流行病学、病因和发病机制的新进展[J].临床儿科杂志，2014，32（2）：189-192.
[2] Singh S，Jindal AK，Pilania RK. Diagnosis of Kawasaki disease [J]. Int J Rheum Dis，2018，21（1）：36-44.
[3] 李小青，匡琳，吴俊，等.川崎病治疗进展[J].现代临床医学，2016，42（5）：328-330.
[4] Liu MY，Liu HM，Wu CH，et al. Risk factors and implications of progressive coronary dilatation in children with Kawasaki disease [J]. BMC Pediatr，2017，17（1）：139.
[5] Soriano-Ramos M，Martínez-Del Val E，Negreira Cepeda S，et al. Risk of coronary artery involvement in Kawasaki disease [J]. Arch Argent Pediatr，2016，114（2）：107-113.
[6] Kim HJ，Choi EH，Lim YJ，et al. The Usefulness of Platelet-derived Microparticle as Biomarker of Antiplatelet Therapy in Kawasaki Disease [J]. J Korean Med Sci，2017，32（7）：1147-1153.
[7] Bonnefoy A，Daenens K，Feys HB，et al. Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting（sub）endothelial VWF from cleavage by ADAMTS13 [J]. Blood，2006，107（3）：955-964.
[8] 陈树宝，黄美容.第10届国际川崎病研讨会概述[J].中华儿科杂志，2012，50（9）：714-717.
[9] 张丽，曹睿，虢艳，等.川崎病冠状动脉病变的超声心动图诊断[J].中华实用儿科临床杂志，2014，29（13）：963-965.
[10] 林敏仪，林艳，廖惠映，等.2007-2017年儿童川崎病流行病学临床特征及并发冠状动脉病变危险因素调查分析[J].中国医学创新，2018，15（28）：56-59.
[11] Reznichenko A，Korstanje R. The role of platelet-activating factor in mesangial pathophysiology [J]. Am J Pathol，2015，185（4）：888-896.
[12] 徐宝华，束进，刘昕，等.血小板活化因子在川崎病中的变化及临床意义[J].中国民康医学，2013，25（24）：23-24.
[13] 王杨记，史卫群，王骞，等.血小板反应蛋白-1和血小板活化因子在川崎病中的变化及意义[J].江苏大学学报：医学版，2018，28（4）：313-315，319.
[14] Tan Z，Yuan Y，Chen S，et al. Plasma Endothelial Microparticles，TNF-a and IL-6 in Kawasaki Disease [J]. Indian Pediatr，2013，50（5）：501-503.
[15] 宋瑞霞，李晓惠，张霆，等.血小板反应蛋白2对川崎病患儿冠状动脉扩张的预测价值[J].中华儿科杂志，2016， 54（4）：259-263.
[16] 刘路琼，董湘玉.川崎病患儿血清血小板反应蛋白1的动态变化[J].第二军医大学学报，2014，35（3）：340-343.
[17] 张超英.血小板反应蛋白在川崎病中的变化及意义[J].中华临床医师杂志：电子版，2013，7（10）：174-175.
[18] 房有福，王凤莲.PAMP和NT-proBNP在预测川崎病冠状动脉损伤中的意义[J].重庆医学，2018，47（4）：486-488.
[19] 李显东，吕军，胡秀学.不对称和对称二甲基精氨酸与川崎病冠状动脉病变相关性分析[J].中国医药导报，2018， 15（11）：63-66.
[20] 张亚杰，李亚蕊.血浆半乳糖凝集素-3在川崎病中的水平及其与冠脉损伤的相关性[J].山西医科大学学报，2017，48（3）：280-282.
[21] 姜松，虎春元，杨映天.NT-proBNP、H_2S和HCgp-39在川崎病中的表达及意义[J].临床和实验医学杂志，2018， 17（13）：1397-1400.
[22] 张清秀，吕志勇，李启亮，等.降钙素原和D-二聚体等联合检测对儿童川崎病早期诊断的应用价值[J].临床和实验医学杂志，2017，16（20）：2060-2063.
[23] 周芳，许君，贾黎红，等.儿童川崎病冠状动脉病变危险因素分析[J].中国现代医生，2018，56（3）：56-59.